Financial Archives - Page 2 of 19 - Green Market Report

William SumnerWilliam SumnerAugust 1, 2018
CVSI.png

3min2130

CV Sciences (CVSI), a company dedicated to developing CBD oil products and novel therapeutics utilizing synthetic CBD, today announced its financial results for the second quarter, which ended on June 30, 2018. The stock popped almost 5% on the news sending the price to approximately $3.31 for a 52-week high. Most recently the company announced that it has applied to list its stock on the NASDAQ Capital Market.

Overall results were positive. Sales for the quarter rose to $12.3 million, representing a 203% increase compared to the same period last year and a 53% increase over the previous quarter.

Gross profit for the quarter was $9.06 million, compared to $2.8 million in the same period last year, and its GAAP net income was $3.1 million. The company’s EBITDA for the quarter was $3.3 million, and its Adjusted EBITDA was $3.8 million. During the same quarter last year, the company’s EBITDA was $811,488, and its Adjusted EBITDA was 280,939.

Over the last quarter, the company increased its retail distribution channels by 11% to 1,968 stores nationwide. The company increased its cash position by $3.3 million in the second quarter, with approximately $6.4 million in unrestricted cash and $7.2 million in total cash.

On August 1, 2018, the company will hold a conference call, led by CV Sciences CEO Joseph Dowling, to provide an operational and financial summary of the second quarter and year-to-date results. The call begins at 4:15 PM EDT and will be available for live stream on the company’s website. For those unable to attend, a recording of the call will be made available for the following two weeks.

“CV Sciences delivered strong financial results for the second quarter of 2018, including our second consecutive quarter of profitability. We also reported record key performance metrics that include triple-digit year-over-year revenue growth and double-digit sales growth on a sequential quarterly comparison,” said CV Sciences CEO, Joseph Dowling, in a statement. “To date, we have been able to successfully execute our planned strategy of aggressively and consistently growing our sales distribution channels, further penetrate the market and increase our market share within the natural products industry…”


StaffStaffAugust 1, 2018
Aphria4.jpg

5min3520

Canadian-based cannabis company Aphria Inc. (APHQF) reported increasing sales for its fourth quarter and year ending May 31, 2018. Revenue for the quarter rose 17% sequentially to $12,026. The increase in the quarter was driven primarily by reporting Broken Coast results for a full quarter versus only one month of revenue in the prior quarter.

Adjusted gross profit for the fourth quarter was $ 9,468, with an adjusted gross margin of 78.7%, compared to $4,903 with an adjusted gross margin of 85.7% in the prior year’s fourth quarter, representing an increase of over 90%. The increase in the adjusted gross margin from the prior quarter was consistent with the increase in revenues combined with improved cost structures.

Net loss for the fourth quarter was $4,992 or $0.06 per share versus the net loss of $2,593 or $0.02 per share in the prior year. The decrease in net income for the quarter relates to $6.5 million in incremental share-based compensation, $3.3 million of costs associated with Aphria International, $8.6 million in net losses on the company’s investment portfolio, all offset by almost $13.0 million in incremental gross profit.

Annual Results 

For the year revenue increased 81% to $36,917 versus $20,438  for 2017. Adjusted gross profit for the year was $27,912 , with an adjusted gross margin of 75.6%, compared to $15,854 , with an adjusted gross margin of 77.6%, representing an increase of over 75%. The increase in adjusted gross profit for the year is consistent with the company’s increase in revenue over the period.

Net income for the year was $29,448 or $0.18 per share, as opposed to $4,198 or $0.04 in the prior year. The increase in net income for the year relates to fair value adjustments associated with biological assets and unrealized gains on the company’s investment portfolio.

Management Comments

“We had a healthy fourth quarter and a solid year with many achievements we are proud of,” said Vic Neufeld , Chief Executive Officer, Aphria. “We are excited and ready to hit the ground running on the first day of legal adult-use. It won’t be without its challenges but we have a plan and the team in place to get it done. We continue to sign supply agreements with provinces and territories, and our Southern Glazer’s sales network partnership is unmatched, ensuring our brands and products are available and represented by retailers across the country.”

“Beyond that, we will continue to extend our industry-leading expertise and experience into global markets. We’ve had an exciting year adding more depth and experience to our senior leadership team that has helped expand our international operations and presence outside of Canada, US and Australia to an additional eight countries, and look forward to continued expansion within LATAM,” continued Neufeld.

Preparing For Adult Use Sales

Aphria suggested that revenue could dip due to its “previously announced decision to discontinue wholesales sales to other licensed producers, to provide increased inventory for the eventual pipeline fill for adult-use and international market opportunities over the next six to nine months.” Aphria has signed MOU‘s with British Columbia, Alberta, Manitoba, Quebec, New Brunswick and the Yukon Territory, with more agreements to be announced in the short-term.

Aphria believes that its low cost of production will help it to be successful against its peers as adult use sales begin. The company reported improved cash costs to produce dried cannabis per gram to $ 0.95, a decrease of $0.01 in the quarter, remaining below $1.00 for the second consecutive quarter.


Debra BorchardtDebra BorchardtJuly 30, 2018
Organigram-Holdings.jpg

3min2520

Canadian-based Organigram Holdings Inc. (OGRMF) stock rose over 2% to approximately $3.43 after the cannabis delivered solid results for its fiscal third quarter. The company reported sales of C$3.7 million for the fiscal third quarter versus last year’s C$1.9 million in the same time period.  The company also reported net income of C$2.8 million for a sequential increase of 162% compared to $1.1 million in the second quarter. This easily topped last year’s third-quarter loss of $C2.3 million.

“Our fiscal third quarter was transformational for the Company,” read the company statement. “Our production capabilities have increased exponentially, we launched our adult recreational brand strategy and have signed agreements with a number of provinces and private retailers as well as announcing key significant investments from both a strategic and international perspective. As we head into the launch of the adult use recreational market we believe Organigram is well positioned to build upon its domestic medical business into becoming a national player in the adult recreational market and a global player in the medical market.”

The company’s cultivation the cost per gram for dried flower came in at C$0.80 per gram “all-in” which includes direct labor and materials, allocated overhead and depreciation. Excluding depreciation, the cost was C$0.58 /gram.

Organigram reported that its cannabis oil sales volume increased 39% sequentially to 768,400 milliliters from the second quarter and jumped 452% over last year’s third quarter. The sales volume for dried flower increased 28% sequentially from the second quarter to 303,428 grams and rose 55% over last year’s 196,129 grams.

The company is in solid financial position with $156 million in cash and short-term investments (up from $34 million at the August 31, 2017 year-end). Still, there is $98 million in long-term debt and convertible debentures.

Last week, Echelon Wealth Partners initiated coverage on Organigram with a speculative buy rating and a $7 price target.

 

Looking Ahead

The company said that its Phase 4a (26 grow rooms) and 4b (27 grow rooms) construction expansions began in Q4 including a substantially complete 40-megawatt (peak capacity) substation worth $4 million – total cost of Phases 4a and 4b (including the $4 million spent on the substation) estimated to be $70 million bringing target production capacity to 89,000 kg/annum. Phase 4c (24 grow rooms) which has an estimated cost of $40 million would bring target production capacity to 113,000 – construction scheduled to begin in January 2019.


William SumnerWilliam SumnerJuly 27, 2018
Curaleaf3-1280x720.png

3min10440

The company behind the brand Curaleaf is going public in Canada. On July 26, 2018, PalliaTech Inc. announced that it has entered into an agreement with Lead Ventures Inc. (LEAD) to combine their businesses, with PalliaTech shareholders gaining a controlling interest in Lead Ventures.

PalliaTech is a holding company specializing in the medical cannabis industry with operations in 10 U.S. states on both the East and West coast. Its subsidiaries are focused on cultivating, processing, and dispensing medical cannabis for the company’s brand, CuraLeaf.

Formerly known as Maccabi Ventures Inc., Lead Ventures is a junior mineral exploration company that acquires, searches for, and evaluates natural properties in Canada.

Although merging with a non-cannabis company is not the most common way of going public, other cannabis companies have successfully completed similar methods.

Earlier this year, MedMen went public in Canada through a reverse takeover of the Canadian public company OutdoorPartner Media. Most recently, Dixie Brands Inc. announced that it too would go public through a reverse takeover of Academy Explorations Limited.

The combined company will retain the name Pallia Tech Inc., and the company’s share will list on the Canadian Securities Exchange (CSE). Outstanding common shares of both companies will be consolidated on a basis that is yet to be determined. All of Lead Venture’s directors and officers will be replaced by nominees named by PalliaTech.

PalliaTech intends to complete a brokered private placement of subscription receipts to accredited investors through a single purpose vehicle. Existing shareholders of Lead Ventures before the completion of the agreement will receive post-consolidated shares of the newly combined company; totaling to CAD$2.16 million, at a price per share equal to the PalliaTech Financing price.

Completion of the agreement is still dependent on several factors, such as shareholder and regulatory approvals. Approval of the transaction by shareholders is expected to occur during an annual general and special shareholder meeting of Lead Ventures. Trading of Lead Ventures’ common shares will remain halted until all the applicable regulatory authorities have accepted all necessary filings.


Debra BorchardtDebra BorchardtJuly 27, 2018
dixie-elixirs-big2-1280x762.jpg

4min6862

Colorado-based Dixie Brands Inc. is engaging in a reverse takeover of Academy Explorations Limited and then will list on the Canadian Securities Exchange. Academy will change its business from mining to the cannabis industry and the former shareholders of Dixie will hold approximately 95% of the
common shares of the resulting company.

“We are delighted to take the iconic Dixie Elixir, as well as our other consumer-focused brands, to the public capital markets in order to bring these well
recognized and highly rated products to enthusiastic consumers across the U.S., as well as to Canada and other international markets, ” said Chuck Smith, President, and CEO of Dixie. “The Canadian capital markets have proved to be an important and critical source of growth funding for U.S. cannabis companies. We are preparing for and anticipate a Q4, 2018 public offering on the CSE which will fund revenue generating production, distribution, and consumer marketing
programs to support our global expansion.”

According to the company statement, “Dixie intends to complete a private placement prior to closing of Dixie shares and warrants for aggregate gross proceeds of between $12,000,000 and $20,000,000, including the conversion of approximately $2,000,000 of debt to be exchanged for Dixie common shares at the same deemed value of Dixie as the private placement, at a price equal to the fully diluted equity capitalization of Dixie prior to the Private Placement valued at
$80,000,000. Each Dixie warrant shall entitle the holder thereof to acquire one Dixie share for $13.95, at an approximate valuation of $150,000,000, exercisable for one year.”

Dixie has three portfolio companies under its umbrella: Dixie Elixirs & Edibles, Aceso Wellness (Hempderived CBD based human dietary supplement), and Therabis (Hemp-derived CBD based pet food supplement). The company currently operates in four U.S. states with an aggressive expansion plan for 2019. Dixie has also executed a license agreement with Auxly Cannabis in May of 2018. This agreement permits Auxly to exclusively produce and distribute Dixie branded products throughout Canada. Dixie’s expansion strategy will be to control manufacturing and distribution in all markets where it participates while simultaneously building a global brand known for its quality and efficacy.

Dixie shareholders will be issued roughly 10.45 Academy shares for every one Dixie share. All of Academy’s officers and directors will resign. The statement also said that pursuant to the terms of the LOI, the company will effect a consolidation of its issued and outstanding common shares prior to closing on a 4:1 basis
resulting in approximately 6,641,808 Academy Shares outstanding on a post-Share Consolidation basis. The 400,000 issued and stock options of Academy will be consolidated into 100,000 Academy Options. Each Academy Option will be exercisable for one Academy Share at an the exercise price of C$0.08 per share on a post-Share Consolidation basis until July 5, 2021.

 

 

 

 


Jeffrey YozwiakJeffrey YozwiakJuly 25, 2018
NutritionalHigh.jpg

4min2274

On July 3, Nutritional High International Inc. (SPLIF) published a press release boasting Q3 revenues of $2,680,444 CAD, an increase of 408% over Q3 2017. That figure, however, differs from the Q3 financial statements Nutritional High filed with SEDAR. Nutritional High’s formal financial statements show lower 2018 Q3 earnings and the discrepancy remains unaccounted for. Nutritional High did not respond to a request for comment.

Nutritional High is a Toronto-based company that distributes edibles, concentrates, and oils. Nutritional High both develops its own products under its FLÏ flagship brand and acquires other brands for distribution and development. On July 18, Nutritional High announced a Letter of Intent to acquire a 51% interest in Bright Green Lights LLC (d/b/a J:MEDS), which produces cannabis-infused lozenges and mints.

In March, Nutritional High acquired Calyx Brands Inc., a California-based distributor, for $3,433,784 CAD. In Q3, Calyx Brands posted sales $1,674,269 CAD, accounting for the majority of Nutritional High’s Q3 2018 revenue. This number is not misstated in Nutritional High’s July 3 press release.

Nutritional High’s Q3 financial statements, though, do not show top-line revenue of $2,680,444 CAD. It’s unclear how the company arrived at this figure. In addition to the sales by Calyx Brands, Nutritional High reported earnings of $585,156 CAD from various asset holdings. Incorporating these earnings brings Nutritional High revenue total to $2,257,425 CAD, still short of their $2,680,444 figure.

Nutritional High reported 408% year-over-year growth by pointing to their Q3 2017 revenues of $527,227 CAD. This was income from asset holdings—specifically, interest on a loan to Palo Verde LLC and rent from real estate holdings. However, Nutritional High’s gross profits show more modest growth. In Q3 2017, Nutritional High’s revenue was entirely profit. But, in Q3 2018, income from their asset holdings was down and Calyx Brands contributed $1,346,722 CAD in COGS. Nutritional High’s gross profits were only $693,821 CAD.

Nutritional High “has been incurring operating losses and cash flow deficits since its inception,” according to their financial statements. In Q3 2018, they reported a net loss of $2,397,163 CAD—roughly the same as in Q3 2017. Nutritional High raised $8 million CAD in Q3 2018 and has $19,227,881 CAD in assets. With a solid amount of cash under its belt, it’s unclear why these numbers don’t add up and why the company didn’t respond for a request for clarity.


StaffStaffJuly 23, 2018
shutterstock_751259302.jpg

5min6262

Acreage Holdings continues to quickly take charge in dominating the U.S. cannabis scene. Today’s news of raising $119 million will comfortably position the company to go public on the Canadian Securities Exchange this year. In addition to raising what could be the largest private round in the U.S. cannabis industry, Acreage completed the roll-up of control positions in several U.S. states.

“The response we received from our investor partners was profoundly encouraging. The combination of monies raised and the rollup cements Acreage as one of the best capitalized companies in the industry with a footprint that is second to none,” Kevin Murphy, founder and CEO of Acreage Holdings said. “This gives us an exceptionally strong investment proposition to bring into the public markets in our upcoming listing.”

Currently, Acreage is one of the largest cannabis companies in the U.S. with a presence in 13 states. Now with the money it has raised, Acreage will be able to acquire additional licenses, brands, and other properties.

Acreage currently owns or operates licenses in 13 states (but is close to pushing that number to 15) and plans to use the monies raised to acquire additional licenses, brands and other properties to increase its reach, breadth of offerings and depth of management team.

“We are planning on listing on the CSE for many reasons, including the positive reception that the Canadian institutional investment community has shown to the U.S. cannabis industry and to Acreage in particular.  Additionally, the CSE has become the exchange of choice for U.S. companies like ours,” Murphy continued.  “The liquidity on the CSE is incredibly attractive to Acreage, and we know that retail investors in the U.S. have become comfortable with that exchange. We expect to see a tremendous response to our offering this fall.”

Initially, the company had planned to raise $50 million, but the addition of former Speaker of the House John Boehner and former Massachusetts governor Bill Weld drew widespread interest from investors. The round was quickly oversubscribed and accomplished in less than three months. In addition to that, Acreage had no need to hire bankers in order to bring in the investors and was able to accomplish this task on its own.
In a move that hasn’t been commonly seen in the cannabis industry, Acreage plans to put its investors before the executive team by making the new shares in the company senior to the management held shares. In a recent interview on the Midas Letter, Murphy said, “Every round of financing that we’ve ever done we’ve subordinated our own shares to those investors because it’s our goal; yes, to enrich ourselves but I often say you know I don’t like losing my own money but I’ve got a very, very hard time losing somebody else’s money and so that’s the way we’ve done it and that’s the message we’ve conveyed to our investors and that is why on this last round of financing that we’ve just done, we were about 5 to 6 times oversubscribed for it.”

“Our objective with our investors is to set the standard in terms of professionalism and competency in order to remove as much risk from cannabis investing as possible,” said George Allen, the President of Acreage Holdings. “It is a mission that will remain paramount to us as we transition from a private to a public investor base.”


Debra BorchardtDebra BorchardtJuly 23, 2018
PotNetwork.jpg

5min2632

Penny stock cannabis company PotNetwork Holdings Inc. (POTN) reversed its recent decision to become a fully reporting SEC company on Sunday. Just a days ago on July 16, PotNetwork said it had filed a Form 10 with the Securities and Exchange Commission (SEC) to become a fully reporting company.

At that time the company stated, “These actions are fundamental to the Company’s goal of heightened transparency for its investors and are expected to bring the Company greater visibility and credibility before global financial markets and investors. The Company also intends to uplist to the OTCQB.”

Yesterday, PotNetworks asked the SEC to withdraw its Form 10 after the company learned that its auditing firm East-West Accounting Services, LLC, Princeton, Florida, had lost its PCAOB certification as a result of a PCAOB disciplinary order specific to deficiencies in an audit conducted in 2015 for an unrelated Dallas, Texas company.

PotNetworks hired the accounting firm in August of 2017. “We believe that the timing for this action is now. In consideration of the amount of momentum built up over the past 6 months, coupled with reported revenues of $5,077,625 for the first 6 months of fiscal 2017, the only logical next step was to initiate the auditing process, whereby the market can recognize the significance and legitimacy of the Company’s recent growth,” stated Gary Blum, Chief Executive Officer, PotNetwork Holding, Inc.

Yet, earlier that year in February, the PCAOB issued a report inspecting East West for its 2016 work. It wrote, “The auditor issued an opinion without satisfying its fundamental obligation to obtain reasonable assurance about whether the financial statements were free of material misstatement.” Yet, the company hired them anyway.

New Cannabis Ventures analyst Alan Brochstein dug through the company’s Form 10 and discovered numerous discrepancies. He wrote, “We have found what appear to be errors in both the company’s Cash Flow Statement and its Income Statement.”

PotNetworks said that it plans to file a revised registration statement as soon as possible. In an apparent attempt to assure shareholders, the company sent out a new press release on Monday stating, “With over $10 million in sales of its Diamond CBD products during the first five months of 2018 compared to sales of $5,077,625 during the first six months of 2017, the Company continues to strengthen its position in the hemp-derived CBD Industry.” The company acts as a middleman for online sales at the website Diamond CBD.

PotNetworks is also planning on changing its name to BioTech Hemp as it believes this name more accurately reflects the business of the company. This is one of just many names changes for Potnetworks. According to the OTC Markets, the company has had the following name changes:

Formerly=United Treatment Centers, Inc. until 7-2015
Formerly=United Treatment Centers, Inc. until 10-2013
Formerly=MyMedicalCD, Ltd. until 1-2009
Note=11-04 State of Incorporation Nevada changed to Wyoming
Formerly=Interactive Solutions Corp. until 11-04
Formerly=Araldica Wineries Ltd. until 2-00
Formerly=H P Capital Corp. until 9-96
Additionally, the company lists itself under the SIC company code classifications as a “4899” or communications company because it runs a news website, yet it is really a retail company selling CBD products.
Stock Performance
The stock was lately trading at 29 cents on the OTC Markets Group, down from its 52-week high of 95 cents, which it hit in January 2018.

Debra BorchardtDebra BorchardtJuly 19, 2018
TGOD3.jpg

3min4400

The Green Organic Dutchman Holdings Ltd. (TGODF) is distributing a dividend that will consist of a warrant in a new corporation called TGOD Acquisitions to its shareholders. The company will do just as the name says – acquire and develop worldwide opportunities.

TGOD said that it had met with many cannabis companies around the world that didn’t quite fit with the company, but believes the properties would benefit their shareholders. The company said that it plans to execute a series of staged financings and acquisitions that would ultimately lead to a late 2018 target IPO date.

“This is an incredible opportunity for TGOD to transfer expertise and monetize our proprietary knowledge from the Canadian marketplace. We will partner with innovative and disruptive companies that we can assist with capital market knowledge and unique retail-exclusive financing methods. The intention is to raise additional capital and list TGOD Acquisitions on the Canadian Securities Exchange. We are excited about this unique opportunity to reward our investors and provide additional value to TGOD shareholders,” said TGOD CEO, Brian Athaide.

Once the spin-out is complete TGOD Acquisitions will operate separately from TGOD and will have its own Board of Directors and management.

Terms

According to a company statement, TGOD will distribute to its shareholders a Warrant to acquire a TGOD Acquisitions Unit for $0.50. Each Unit will consist of one share plus an additional warrant for the investor. This additional warrant (the “Additional Warrant”) will be triggered by a subsequent financing to occur following the initial $0.50 offering.

The distribution will be paid on the basis of one Warrant for every 6.67 TGOD shares owned on the record date, to be fixed by the Board of Directors of TGOD following satisfaction of the conditions for the Arrangement.

TGOD and TGOD Acquisitions will enter into a repayable funding agreement, whereby TGOD will provide $25,000,000 of working capital to TGOD Acquisitions. This will be repayable by TGOD Acquisitions prior to completion of any investment. In consideration for the funding agreement, TGOD Acquisitions will issue a restricted warrant to purchase 50 million common shares for a period of 25 years from the date upon which the shares of TGOD Acquisitions commence trading on the Canadian Securities Exchange.

“We have developed a significant amount of intrinsic value from years of corporate development at TGOD,” said Brian Athaide. “Capitalizing on these efforts will add value to both TGOD’s balance sheet and the investment portfolios of our shareholders,” continued Athaide.


StaffStaffJuly 19, 2018
shutterstock_513689059-1280x854.jpg

5min12870

Part 2 of 8 of the Cannabis Trends for 2018: U.S. companies run north of the border and IPOs are on the rise.

Over the next year expect an increase of cannabis companies to start going public in Canada instead of the United States. Although the U.S. market has great potential in the long run, there are a lot of short term advantages to going public in Canada.

The first, and most obvious reason, is that Canada has legalized recreational cannabis sales.

Sure, nine states have legalized recreational cannabis, but it’s still federally illegal. US cannabis companies continuously have to look over their shoulders, hoping that the federal government isn’t about to kick down their door and make their business close its doors for good. Not to mention the fact that the entire U.S. market still  operates as cash-only, with extremely limited access to banking services.

Put yourself in the position of a cannabis business owner: Would you rather operate in a market that has the *potential* of being more profitable but has no access to banking services and puts you at risk of being arrested? Or would you want to operate in a market that carries little legal risk and you can actually open a bank account? For many entrepreneurs, it’s a pretty simply choice.

One company that is not afraid to do business in both the United States and Canada is Sunniva. Headquartered in Calgary, Canada, Sunniva is on the fast track to becoming one of the first cannabis companies to be licensed in both Canada and California, which is one of the world’s largest cannabis markets.

Legality aside, there’s also the issue listing requirements in the U.S. Companies have to be meet very strict requirements in order to become listed on the New York Stock Exchange (NYSE) or NASDAQ. For example, in order to become listed on the NYSE you need to have publicly held securities that are valued at a minimum of $100 million. Likewise, companies hoping to go on NASDAQ need a pre-tax income of $11 million for an aggregate of three years.

Contrast that with the Canadian exchanges, where companies on the TSX only need a pre-tax income from the previous year totaling $300,000. Those are not the only requirements, of course, but from there you can get a pretty clear idea of how difficult it is to make it on the NYSE or NASDAQ compared to the CSE or TSX.

The vast majority of “cannabis companies” listed on the NYSE and NASDAQ are biopharmaceutical companies, like GW Pharmaceuticals, that aren’t primarily cannabis companies. The only two companies that are purely cannabis companies that are publicly listed in the United States is Cronos Group and Canopy Growth.

With fewer barriers and fewer risks, numerous companies that previously started as U.S. based companies have begun moving operations north of the border and are making preparations to go public. Some of those companies include Acreage Holdings, Dixie Brands Inc., and MJIC Inc.

In the short term, expect an exodus of cannabis companies either going public or completely moving their operations to Canada and expect them to stay there until the United States finally decides to tackle federal cannabis reform.



About Us

The Green Market Report focuses on the financial news of the rapidly growing cannabis industry. Our target approach filters out the daily noise and does a deep dive into the financial, business and economic side of the cannabis industry. Our team is cultivating the industry’s critical news into one source and providing open source insights and data analysis


READ MORE



Recent Tweets

@GreenMarketRpt – 3 hours

RT : Here are the top financial cannabis news stories for the week ending October 12, 2018…

Back to Top

You have Successfully Subscribed!